Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:CRBU NASDAQ:FTLF NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.39-1.7%$3.61$2.76▼$6.98$170.56M1.19153,785 shs75,218 shsCRBUCaribou Biosciences$1.80-1.6%$1.92$0.66▼$3.00$170.42M2.54614,834 shs1.06 million shsFTLFFitLife Brands$18.56+1.9%$15.70$9.83▼$19.19$171.01M0.6513,221 shs17,706 shsTELOTelomir Pharmaceuticals$1.30-2.3%$1.55$1.12▼$8.40$42.93M-0.734.66 million shs287,577 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-1.74%+2.11%+16.10%-15.04%-42.64%CRBUCaribou Biosciences-1.64%-2.17%-9.09%+40.63%-11.33%FTLFFitLife Brands+1.92%-2.62%+11.74%+36.17%+13.80%TELOTelomir Pharmaceuticals-2.26%-4.41%-12.75%-26.14%-78.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.39-1.7%$3.61$2.76▼$6.98$170.56M1.19153,785 shs75,218 shsCRBUCaribou Biosciences$1.80-1.6%$1.92$0.66▼$3.00$170.42M2.54614,834 shs1.06 million shsFTLFFitLife Brands$18.56+1.9%$15.70$9.83▼$19.19$171.01M0.6513,221 shs17,706 shsTELOTelomir Pharmaceuticals$1.30-2.3%$1.55$1.12▼$8.40$42.93M-0.734.66 million shs287,577 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-1.74%+2.11%+16.10%-15.04%-42.64%CRBUCaribou Biosciences-1.64%-2.17%-9.09%+40.63%-11.33%FTLFFitLife Brands+1.92%-2.62%+11.74%+36.17%+13.80%TELOTelomir Pharmaceuticals-2.26%-4.41%-12.75%-26.14%-78.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.50Moderate Buy$6.0076.99% UpsideCRBUCaribou Biosciences 3.00Buy$6.67270.37% UpsideFTLFFitLife Brands 2.67Moderate Buy$23.0023.92% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.001,053.85% UpsideCurrent Analyst Ratings BreakdownLatest TELO, FTLF, BTMD, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025FTLFFitLife BrandsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.008/7/2025BTMDbioteB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$8.00 ➝ $4.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$197.19M0.85$0.75 per share4.50($2.78) per share-1.22CRBUCaribou Biosciences$9.99M16.78N/AN/A$2.79 per share0.65FTLFFitLife Brands$64.47M2.70$1.03 per share17.97$3.93 per share4.72TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.903.776.28N/A15.73%-21.00%18.26%11/11/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)FTLFFitLife Brands$8.98M$0.8422.1016.87N/A12.63%21.70%13.45%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.54N/AN/AN/AN/A-4,595.08%-1,750.91%11/11/2025 (Estimated)Latest TELO, FTLF, BTMD, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 million8/14/2025Q2 2025TELOTelomir Pharmaceuticals-$0.08-$0.17-$0.09-$0.17N/AN/A8/12/2025Q2 2025CRBUCaribou Biosciences-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million8/6/2025Q2 2025BTMDbiote$0.06$0.10+$0.04$0.10$49.52 million$48.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A0.980.74CRBUCaribou BiosciencesN/A6.666.66FTLFFitLife Brands0.151.710.81TELOTelomir PharmaceuticalsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%CRBUCaribou Biosciences77.51%FTLFFitLife Brands2.32%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBTMDbiote24.00%CRBUCaribou Biosciences9.50%FTLFFitLife Brands61.40%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19449.44 million37.57 millionNot OptionableCRBUCaribou Biosciences10093.12 million84.28 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableTELOTelomir Pharmaceuticals132.28 millionN/AN/ATELO, FTLF, BTMD, and CRBU HeadlinesRecent News About These CompaniesTELO Releases Cancer Suppressing ResultsSeptember 9, 2025 | msn.comTelomir Pharmaceuticals announces preclinical cancer data on Telomir-1September 9, 2025 | msn.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor ...September 9, 2025 | charlotteobserver.comCTelomir Pharmaceuticals Unveils Promising Preclinical Cancer DataSeptember 9, 2025 | tipranks.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and ChemotherapySeptember 9, 2025 | accessnewswire.comATelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest UpdateSeptember 8, 2025 | americanbankingnews.comTelomir Pharmaceuticals Completes $2.9 Million Stock SaleSeptember 4, 2025 | tipranks.comTelomir stock soars after drug candidate shows promising epigenetic effectsAugust 28, 2025 | za.investing.comTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging ...August 28, 2025 | kansascity.comKTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related DiseasesAugust 28, 2025 | accessnewswire.comATELO Makes Progress Toward Human TrialsAugust 15, 2025 | msn.comTelomir-1 inhibits key histone demethylase enzymes in vitroAugust 12, 2025 | bioworld.comBTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...August 8, 2025 | kansascity.comKTelomir Flat on Trial Data ReleaseAugust 7, 2025 | baystreet.caTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic DysfunctionAugust 7, 2025 | accessnewswire.comATelomir Pharmaceuticals Announces Promising Preclinical ResultsJuly 26, 2025 | theglobeandmail.comTelomir Pharmaceuticals stock surges on promising Progeria treatment resultsJuly 25, 2025 | investing.comTELO Announces Another Important BreakthroughJuly 25, 2025 | finance.yahoo.comTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson'sJuly 24, 2025 | accessnewswire.comATelomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer ResultsJuly 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTELO, FTLF, BTMD, and CRBU Company Descriptionsbiote NASDAQ:BTMD$3.39 -0.06 (-1.74%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$3.39 +0.00 (+0.03%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Caribou Biosciences NASDAQ:CRBU$1.80 -0.03 (-1.64%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.84 +0.04 (+2.22%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.FitLife Brands NASDAQ:FTLF$18.56 +0.35 (+1.92%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$18.58 +0.02 (+0.08%) As of 09/16/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Telomir Pharmaceuticals NASDAQ:TELO$1.30 -0.03 (-2.26%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.30 0.00 (0.00%) As of 06:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
